Taken together, these results underscore the central involvement of Hsp90 in AD pathogenesis and support the concept that its inhibition - especially through agents like RGRN - 305 - may represent a novel therapeutic strategy capable of modulating key inflammatory and immune pathways in AD (30). This evidence concerns the gene HSP90AA1 and Alzheimer disease.